| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1344 | 2021 |
| PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma MR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ... New England Journal of Medicine 379 (4), 341-351, 2018 | 1262 | 2018 |
| Darolutamide and survival in metastatic, hormone-sensitive prostate cancer MR Smith, M Hussain, F Saad, K Fizazi, CN Sternberg, ED Crawford, ... New England Journal of Medicine 386 (12), 1132-1142, 2022 | 491 | 2022 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 402 | 2021 |
| Tumor-treating fields: a fourth modality in cancer treatment EJ Mun, HM Babiker, U Weinberg, ED Kirson, DD Von Hoff Clinical Cancer Research 24 (2), 266-275, 2018 | 301 | 2018 |
| The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis M Oh, N Alkhushaym, S Fallatah, A Althagafi, R Aljadeed, Y Alsowaida, ... The Prostate 79 (8), 880-895, 2019 | 148 | 2019 |
| Physiology, coagulation pathways R Chaudhry, SM Usama, HM Babiker | 132 | 2018 |
| Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system HM Babiker, A McBride, M Newton, LM Boehmer, AG Drucker, M Gowan, ... Critical reviews in oncology/hematology 126, 186-200, 2018 | 101 | 2018 |
| The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC PN Aguiar Jr, LA Perry, J Penny-Dimri, H Babiker, H Tadokoro, ... Annals of Oncology 28 (9), 2256-2263, 2017 | 101 | 2017 |
| Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA P Barata, N Agarwal, R Nussenzveig, B Gerendash, E Jaeger, W Hatton, ... Journal for immunotherapy of cancer 8 (2), 2020 | 85 | 2020 |
| Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC) S Chandana, HM Babiker, D Mahadevan Expert Opinion on Investigational Drugs 28 (2), 161-177, 2019 | 73 | 2019 |
| SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt MAM Iesa, MEM Osman, MA Hassan, AIA Dirar, N Abuzeid, JJ Mancuso, ... New microbes and new infections 38, 100817, 2020 | 71 | 2020 |
| Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: a phase 1b/2 pilot clinical trial GS Jameson, E Borazanci, HM Babiker, E Poplin, AA Niewiarowska, ... JAMA oncology 6 (1), 125-132, 2020 | 69 | 2020 |
| StatPearls R Chaudhry, SM Usama, HM Babiker Treasure Island (FL) StatPearls Publishing, 2021 | 58 | 2021 |
| Ublituximab for the treatment of CD20 positive B-cell malignancies HM Babiker, AE Glode, LS Cooke, D Mahadevan Expert Opinion on Investigational Drugs 27 (4), 407-412, 2018 | 52 | 2018 |
| Hodgkin lymphoma H Kaseb, HM Babiker | 44 | 2018 |
| Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma HM Babiker, IB Riaz, M Husnain, MJ Borad Oncolytic virotherapy, 11-18, 2017 | 43 | 2017 |
| Neuroblastoma of the elderly, an oncologist’s nightmare: case presentation, literature review and SEER database analysis E Rogowitz, HM Babiker, M Kanaan, RA Millius, QS Ringenberg, ... Experimental Hematology & Oncology 3, 1-7, 2014 | 43 | 2014 |
| Clinical outcomes with first-line chemotherapy in a large retrospective study of patients with metastatic pancreatic cancer treated in a US community oncology setting TH Cartwright, M Parisi, JL Espirito, TW Wilson, C Pelletier, M Patel, ... Drugs-real world outcomes 5, 149-159, 2018 | 41 | 2018 |
| Gastric cancer SKR Mukkamalla, A Recio-Boiles, HM Babiker | 41* | 2017 |
